More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. by Spinthakis, Nikolaos et al.
More, More, More: Reducing Thrombosis in Acute Coronary
Syndromes Beyond Dual Antiplatelet Therapy—Current Data and
Future Directions
Nikolaos Spinthakis, MBBS; Mohamed Farag, MSc; Bianca Rocca, MD, PhD; Diana A. Gorog, MBBS, MD, PhD, FRCP, FESC
C ommon to the pathogenesis of acute coronary syn-dromes (ACS) is the formation of arterial thrombus,
which results from platelet activation and triggering of the
coagulation cascade.1 To attenuate the risk of future throm-
botic events, patients with ACS are treated with dual
antiplatelet therapy (DAPT), namely, the combination of
aspirin with a P2Y12 inhibitor, such as clopidogrel, ticagrelor,
or prasugrel. Despite DAPT, some 10% of ACS patients
experience recurrent major adverse cardiovascular events
over the subsequent 30 days,2 driving the quest for more
effective inhibition of thrombotic pathways. In this review, we
provide an overview of studies to date and those ongoing that
aim to deliver more effective combinations of antithrombotic
agents to patients with recent ACS. We have chosen to
conﬁne the review to ACS patients without atrial ﬁbrilla-
tion because those with atrial ﬁbrillation have a clear
indication for combination therapy that includes oral
anticoagulation and should, we feel, be treated as a separate
cohort.
In this article, we discuss the limitations of the currently
available clinical trial data and future directions, with sugges-
tions for how practice might change to reduce the risk of
coronary thrombosis in those at greatest risk, with minimal
impact on bleeding.
Beyond DAPT: Triple-Therapy Combinations in
ACS
Cilostazol
Cilostazol, a selective phosphodiesterase type 3 inhibitor,
reduces platelet aggregation induced by collagen, 50-ADP,
epinephrine, and arachidonic acid and improves endothelial
cell function.3 Studies comparing triple therapy (TT) compris-
ing DAPT plus cilostazol versus DAPT alone have been
generally small randomized trials with largely negative
results.4 The CILON-T (Inﬂuence of Cilostazol-Based Triple
Antiplatelet Therapy on Ischemic Complications After Drug-
Eluting Stent Implantation) trial randomized 960 patients
undergoing percutaneous coronary intervention (PCI) to DAPT
(aspirin and clopidogrel) or TT (DAPT and cilostazol). Despite
reduction in platelet reactivity, addition of cilostazol did not
signiﬁcantly reduce the composite of cardiac death, nonfatal
myocardial infarction (MI), ischemic stroke, or target lesion
revascularization (8.5% versus 9.2%; 95% conﬁdence interval
[CI], 0.59–1.46; P=0.74).5 The HOST-ASSURE (Harmonizing
Optimal Strategy for Treatment of Coronary Artery Stenosis–
Safety and Effectiveness of Drug-Eluting Stents and Anti-
platelet Regimen) trial of 3755 patients undergoing PCI did
not demonstrate the superiority of TT (conventional DAPT with
cilostazol) over DAPT (double-dose clopidogrel and aspirin)
with respect to 1-month composite clinical outcomes (1.2%
versus 1.4%; 95% CI, 0.49–1.48; Psuperiority=0.558).
6
A meta-analysis of randomized and observational studies
(n=11) of high-risk ACS patients undergoing PCI, using
DerSimonian and Laird principles, showed that TT reduced
all-cause mortality compared with DAPT (odds ratio [OR]:
0.72; 95% CI, 0.61–0.85; P<0.001) without an effect on MI
(OR: 0.97; 95% CI, 0.63–1.51; P=0.901), target vessel
revascularization (TVR; OR: 0.90; 95% CI 0.65–1.23;
P=0.491), stroke (OR: 0.63; 95% CI, 0.32–1.21; P=0.163),
or bleeding (OR: 1.07; 95% CI, 0.60–1.90; P=0.809).7
However, a larger meta-analysis of 19 randomized trials and
registries comparing aspirin and clopidogrel against TT with
cilostazol in 7464 patients with ACS undergoing PCI8 showed
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that TT did not signiﬁcantly reduce major adverse cardiovas-
cular events or mortality (relative risk [RR]: 0.77; 95% CI,
0.55–1.09; P=0.15) but signiﬁcantly reduced TVR (RR: 0.65;
95% CI, 0.55–0.77; P<0.00001). Cilostazol is restricted to use
as a second-line agent in patients with claudication and is not
currently recommended by the European Society of Cardiol-
ogy (ESC)9 or American College of Cardiology/American Heart
Association (ACC/AHA) guidelines,10,11 nor is it approved for
ACS.
Warfarin
The addition of standard-dose warfarin to DAPT with clopido-
grel after ACS has been assessed only in small registries that
showed unacceptable increases in bleeding. Warfarin is the
most commonly used vitamin K antagonist, which inhibits the
production of vitamin K–dependent coagulation factors II, VII,
IX, and X and, to a lesser extent, proteins C and S. This leads
to a dose- and time-dependent anticoagulation effect that
requires close monitoring.12 A registry of 40 812 ACS
patients treated with multiple different regimens revealed a
3-fold increase in bleeding with TT comprising warfarin,
clopidogrel, and aspirin compared with DAPT.13
The WOEST (What Is the Optimal Antiplatelet and Antico-
agulant Therapy in Patients With Oral Anticoagulation and
Coronary Stenting) open-label randomized controlled trial
compared dual antithrombotic therapy (warfarin and clopido-
grel) with TT (warfarin, aspirin, and clopidogrel) in patients
undergoing PCI with an indication for anticoagulation, mainly
atrial ﬁbrillation.14 A third of patients had ACS. TT signiﬁcantly
increased bleeding compared with dual therapy (44.4% versus
19.4%; 95% CI, 0.26–0.50; P<0.0001) and increased the risk
of the composite of all-cause death, MI, stroke, TVR, and stent
thrombosis, driven by an increase in all-cause mortality (6.3%
versus 2.5%, P=0.027). Consequently, the ESC guidelines on
myocardial revascularization and the ACC/AHA guidelines
recommend reserving TT with warfarin and DAPT to a
short period after PCI in those with an indication for anti-
coagulation.9,15
Thrombin Receptor Antagonism
A key mediator of platelet activation is thrombin, which binds
to protease-activated receptor 1 (PAR-1) and PAR-4 on the
platelet surface in humans (Figure 1). Vorapaxar is the sole
approved PAR-1 inhibitor.
The addition of vorapaxar to single antiplatelet therapy or
DAPT with clopidogrel was assessed in 26 449 stable patients
with a history of MI, stroke, or peripheral vascular disease in
the TRA-2P (Thrombin Receptor Antagonist in Secondary
Prevention of Atherothrombotic Ischemic Events) trial, which
was prematurely terminated because of excess bleeding in
patients with prior stroke. The addition of vorapaxar affected
the primary end point (a composite of cardiovascular death,
MI, or stroke; 9.3% versus 10.5%, P<0.001) and reduced the
major secondary end point (composite of cardiovascular
death, MI, stroke, or recurrent ischemia leading to urgent
coronary revascularization; 11.2% versus 12.4%, P=0.001),
driven by a lower rate of MI (5.2% versus 6.1%, P=0.001;
Figure 2). Vorapaxar increased major bleeding regardless of
the classiﬁcation used (GUSTO [Global Use of Strategies to
Open Occluded Coronary Arteries]: 4.2% versus 2.5%,
P=0.001; non–coronary artery bypass grafting–related TIMI
[Thrombolysis in Myocardial Infarction], major: 2.8% versus
1.8%, P<0.001) as well as intracranial hemorrhage (1% versus
0.5%, P<0.001).16 In the subgroup analysis of MI patients,
vorapaxar signiﬁcantly reduced the primary efﬁcacy end point
(8.1% versus 9.7%, P<0.0001), particularly in high-risk
patients, albeit with a signiﬁcant increase in GUSTO moderate
or severe bleeding (3.4% versus 2.1%, P<0.000117; Figure 2).
Vorapaxar was also assessed in 12 944 patients with
recent ACS in the TRACER (Thrombin Receptor Antagonist for
Clinical Event Reduction in ACS) trial, which was terminated
prematurely because of excess bleeding.19 Patients were
randomized to vorapaxar or placebo in addition to DAPT
(aspirin and clopidogrel; Table). Over a median follow-up of
30 months, moderate and severe GUSTO bleeding occurred
more frequently with vorapaxar than placebo (7.2% versus
5.2%, P<0.001), most notably, intracranial hemorrhage (1.1%
versus 0.2%, P<0.001), without signiﬁcant reduction in the
primary composite efﬁcacy end point of cardiovascular death,
MI, stroke, recurrent ischemia requiring rehospitalization or
urgent coronary revascularization (18.5% versus 19.9%; 95%
CI, 0.85–1.01; P=0.07). The “harder” secondary efﬁcacy end
point of the composite of cardiovascular death, MI, and stroke
was lower with vorapaxar than placebo (14.7% versus 16.4%,
P=0.0219; Figure 2). Although vorapaxar is not approved in
patients with recent ACS, it is approved as add-on therapy to
aspirin or DAPT including clopidogrel in high-risk patients
without previous stroke and with prior MI, between 2 weeks
and 12 months from the acute event, based on the prespec-
iﬁed MI stratum of TRA-2P.17 Vorapaxar has never been
tested in combination with ticagrelor or prasugrel and is
contraindicated in conjunction with these agents. The 2015
ESC guidelines on non–ST-segment–elevation ACS state that
although vorapaxar is approved “for reducing ischemic events
in patients with a history of MI, the beneﬁt of vorapaxar in
addition to aspirin and clopidogrel is modest and must be
carefully weighed against the increase in bleeding events,
including intracranial hemorrhage.”20 The ACC/AHA guideline
for the management of patients with non–ST-segment–
elevation ACS10 makes no mention of vorapaxar, and the
2013 ACCF/AHA guideline for the management of ST-
segment–elevation MI (STEMI) states that “more information
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speciﬁc to patients with STEMI is needed with regard to the
use of prasugrel, ticagrelor, novel factor Xa (FXa) and factor IIa
(FIIa) antagonists, and platelet protease–activated receptor 1
antagonists.”11
Direct Oral FXa Inhibition
Direct FXa inhibitors are a class of anticoagulant drugs that
act directly on factor X in the coagulation cascade and inhibit
the action of FXa, namely, the conversion of prothrombin into
thrombin (Figure 1).
The dose-ﬁnding, phase II, ATLAS ACS-TIMI 46 (Anti-Xa
Therapy to Lower Cardiovascular Events in Addition to
Standard Therapy in Subjects With Acute Coronary
Syndrome–Thrombolysis in Myocardial Infarction 46)23 study
assessed the safety and efﬁcacy of the direct oral FXa
inhibitor rivaroxaban (5, 10, 15, or 20 mg once or twice daily)
in addition to DAPT (with clopidogrel) or single antiplatelet
therapy with low-dose aspirin in 3941 patients with recent
ACS. Bleeding complications increased in a dose-dependent
manner in all TT groups (P<0.0001). The subsequent ATLAS
ACS 2-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular
Events in Addition to Standard Therapy in Subjects With Acute
Coronary Syndrome–Thrombolysis in Myocardial Infarction
51) study—a phase III, double-blind, randomized, placebo-
controlled trial—compared the addition of 2.5 or 5 mg BID
rivaroxaban to DAPT with clopidogrel in 15 526 patients with
ACS.21 The 1-year primary efﬁcacy end point, a composite of
Figure 1. Platelet activation and aggregation and sites of action of antiplatelet drugs. Platelet activation can occur via multiple pathways that
include, among others, von Willebrand factor, collagen, thromboxane A2 (TxA2), and ADP via P2Y12 receptors and thrombin via protease
activated receptors PAR-1 and PAR-4. Platelet activation results in conformational change, release of a and dense granule contents, and
activation of glycoprotein (GP) IIb/IIIa leading to platelet aggregation. cAMP is an inhibitor of GPIIb/IIIa and therefore regulates platelet
aggregation. Phosphodiesterase (PDE) converts cAMP to AMP, which is the inactive compound. Cilostazol is a selective PDE3 inhibitor reducing
platelet aggregation. COX indicates cyclooxygenase; FXa, factor Xa.
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cardiovascular death, MI, and stroke, was signiﬁcantly
reduced by the combined doses of rivaroxaban (8.9% versus
10.7%, P=0.008) and each dose alone (2.5 mg: 9.1% versus
10.7%, P=0.02; 5 mg: 8.8% versus 10.7%, P=0.03) compared
with placebo (Figure 2).18 Rivaroxaban at the 2.5-mg dose
signiﬁcantly reduced cardiovascular death compared with
placebo (2.7% versus 4.1%, P=0.002). In contrast, this was not
seen with the addition of 5 mg rivaroxaban compared with
placebo (4% versus 4.1%, P=0.63). In the comparison of the 2
doses of rivaroxaban (2.5 versus 5 mg), the rates of cardio-
vascular death and all-cause mortality were signiﬁcantly
different for both comparisons (P=0.009). Subgroup analysis
showed that rivaroxaban reduced the primary efﬁcacy end
point in STEMI patients (8.4% versus 10.6%, P=0.019)24 and
reduced stent thrombosis compared with placebo (1.9%
versus 1.5%, P=0.017),25 and the reduction in the primary
efﬁcacy end point in patients with STEMI appeared to become
apparent as early as 30 days after the index event.24
Rivaroxaban combined doses, compared with placebo, signif-
icantly increased the rate of non–coronary artery bypass graft-
ing–related TIMI major bleeding (2.1% versus 0.6%, P<0.001)
and intracranial bleeding (0.6% versus 0.2%, P=0.009) but not
fatal bleeding (0.3% versus 0.2%, P=0.66),21 and the rates of
non–coronary artery bypass grafting–related TIMI major
bleeding were similar with the 2.5- and 5-mg BID doses
(1.8% versus 2.4%, P=0.12).
Rivaroxaban 2.5 mg BID received approval for the preven-
tion of atherothrombotic events in patients after ACS with
elevated cardiac biomarkers. The 2017 ESC guidelines for the
management of acute MI in patients presenting with an ST-
segment–elevation state that rivaroxaban 2.5 mg BID may be
considered in selected patients who receive aspirin and
A
B
Figure 2. Forest plot of the major triple therapy (TT) studies. A, Primary safety outcomes reported on major TT studies. Bleeding results are
reported as odds ratios (ORs) and 95% conﬁdence intervals (CIs). B, Primary efﬁcacy outcomes reported on major TT studies. Ischemic results
are reported as ORs and 95% CIs. Pooled ORs were calculated for bleeding and ischemic outcomes using a random-effect model by the method
of DerSimonian and Laird.18 Forest plots are used to represent the meta-analysis graphically and to show the degree of heterogeneity between
studies. DAPT indicates dual antiplatelet therapy.
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clopidogrel after STEMI and who are at low bleeding risk
(class IIb, level of evidence B).26 The 2015 ESC guideline for
the management of non–ST-segment–elevation ACS states
that “rivaroxaban 2.5 mg twice daily, while not recommended
in those receiving ticagrelor or prasugrel, might be considered
in combination with aspirin and clopidogrel if ticagrelor and
prasugrel are not available for NSTEMI [non-STEMI] patients
who have high ischemic and low bleeding risks” (class IIb,
level of evidence B).20 It is contraindicated in patients with
prior ischemic stroke or transient ischemic attack and
cautioned in those aged >75 years or weighing <60 kg
because of high bleeding risk in older and/or underweight
patients. The ACC/AHA guideline for the management of
patients with non–ST-segment–elevation ACS10 states,
“Although there are some data on therapy with aspirin,
clopidogrel, and warfarin, there is sparse information on the
use of newer P2Y12 inhibitors (prasugrel, ticagrelor), direct
thrombin inhibitor (dabigatran), or factor-Xa inhibitors (ri-
varoxaban, apixaban) in patients receiving triple therapy.”
The more recently published GEMINI ACS 1 (A Study to
Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid
in Addition to Either Clopidogrel or Ticagrelor Therapy in
Participants With Acute Coronary Syndrome) study was a
phase II randomized trial of 3037 patients with ACS comparing
aspirin or rivaroxaban 2.5 mg BID in addition to clopidogrel or
ticagrelor.27 The primary end point was non–coronary artery
bypass grafting–related TIMI clinically signiﬁcant bleeding.
There was no signiﬁcant difference between rivaroxaban and
aspirin with respect to the primary outcome (5% versus 5%;
95% CI, 0.80–1.50; P=0.584). Moreover, among patients
receiving ticagrelor, there was no difference in bleeding
whether they were assigned to receive concomitant aspirin or
Table. Main Characteristics of Phase III Studies Assessing TT in Patients With ACS Without Atrial Fibrillation
Study ATLAS ACS2-TIMI5121 APPRAISE-222 TRACER19 TRA-2P16
Type Double-blind
placebo-controlled
phase III
Double-blind
placebo-controlled
phase III
Double-blind
placebo-controlled
phase III
Double-blind
placebo-controlled
phase III
Antithrombotic agent Rivaroxaban Apixaban Vorapaxar Vorapaxar
Patients, n 15 526 7392 12 944 26 449
Clinical presentation, %
STEMI 50 40 0 0
Non-STEMI 26 42 100 0
Unstable angina 24 18 0 0
PCI for index admission, % 60 44 57 0
DAPT use, % 93 81 92 62
P2Y12 inhibitor use Clopidogrel Clopidogrel Clopidogrel Clopidogrel
Duration of treatment, mo 13 8 12 12
Dose 2.5 mg BID, 5 mg
BID, or placebo
5 mg BID or placebo 2.5 mg once daily or placebo 2.5 mg once daily or placebo
Primary safety end point TIMI major bleeding
not related to CABG
TIMI major bleeding
not related to CABG
TIMI clinically significant
bleeding and moderate or
severe bleeding GUSTO
TIMI clinically significant
bleeding and moderate or
severe bleeding GUSTO
Safety outcome, HR
(95% CI); P value
2.5 mg BID: 3.46
(2.08–5.77); P<0.001
5 mg BID: 4.47
(2.71–7.36); P<0.001
5 mg BID: 2.59
(1.40–4.46); P=0.001
2.5 mg once daily: 1.35
(1.16–1.58); P<0.001
2.5 mg once daily: 1.66
(1.43–1.93); P<0.001
Primary efficacy end point CV death, MI, stroke CV death, MI, or
ischemic stroke
CV death, MI, stroke,
recurrent ischemia with
rehospitalization or urgent
revascularization
CV death, MI, or stroke
Efficacy outcome,
HR (95% CI); P value
2.5 mg BID: 0.84
(0.72–0.97); P=0.007
5 mg BID: 0.85
(0.73–0.98); P=0.03
5 mg BID: 0.95
(0.80–1.11); P=0.510
2.5 mg once daily:
0.92 (0.85–1.01); P=0.07
2.5 mg once daily:
0.87 (0.80–0.94); P<0.001
ACS indicates acute coronary syndromes; CABG, coronary artery bypass grafting; CI, conﬁdence interval; CV, cardiovascular; DAPT, dual antiplatelet therapy; GUSTO, Global Use of
Strategies to Open Occluded Arteries; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; TIMI,
Thrombolysis in Myocardial Infarction; TT, triple therapy.
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rivaroxaban and no difference compared with clopidogrel
(non– coronary artery bypass grafting–related TIMI clinically
signiﬁcant bleeding 7% versus 6% [95% CI, 0.79–1.68]; 3%
versus 3% [95% CI, 0.53–1.171]; Pinteraction=0.588).
Although phase II trials are not powered to assess efﬁcacy,
there was nevertheless no signal for reduction in ischemic end
points with rivaroxaban (5% versus 5%; 95% CI, 0.77–1.46;
P=0.731). Similarly, the study was not powered for assessing
ischemic end points, so no deﬁnite conclusions about the
safety of the combination of rivaroxaban with a P2Y12 inhibitor
versus standard DAPT therapy can be drawn.
The addition of apixaban, a direct oral FXa inhibitor, to single
antiplatelet therapy or DAPT was evaluated in the phase II dose-
ﬁnding APPRAISE (Apixaban for Prevention of Acute Ischemic
andSafetyEvents) study.28Some1700patientswith recentACS
were randomized to apixaban 2.5 mg BID, 10 mg once daily,
10 mgBID, 20 mgonce daily, or placebo. Apixaban signiﬁcantly
increased major or clinically relevant nonmajor bleeding com-
pared with placebo in a dose-dependent manner. This led to
APPRAISE-2 (Apixaban for Prevention of Acute Ischemic and
Safety Events 2), a phase III, randomized, double-blind, placebo-
controlled trial assessing the safety and efﬁcacy of adding
apixaban 5 mgBID toDAPT in 7392 patients with recent ACS.22
Apixaban did not signiﬁcantly affect the primary efﬁcacy end
point of the composite of cardiovascular death,MI, and ischemic
stroke (7.5% versus 7.9%; 95% CI, 0.80–1.11; P=0.51) but
signiﬁcantly increased TIMI major bleeding (1.3% versus 0.5%;
95%CI, 1.50–4.46;P=0.001), including fatal bleeding, leading to
premature termination of the trial (Figure 2).
The addition of darexaban, another FXa inhibitor, to DAPT
in ACS patients was examined in the phase II RUBY-1 (Study
Evaluating Safety, Tolerability, and Efﬁcacy of YM150 in
Subjects With Acute Coronary Syndromes) trial.29 Darexaban
dose-dependently increased TIMI major bleeding compared
with placebo (0.6% versus 0.3%; 95% CI, 1.13–4.60; P=0.022),
and although not powered to assess efﬁcacy outcomes, there
was no observed difference between groups (5.6% versus
4.4%; P value not signiﬁcant).
The phase II dose-ﬁnding AXIOM (Phase 2 Study of TAK-
442, an Oral Factor Xa Inhibitor, in Patients Following Acute
Coronary Syndrome) study assessed the addition of letaxaban
or placebo to DAPT in 2753 patients with recent ACS.30 There
was no difference in major bleeding (0.9% versus 0.5%; 95%
CI, 0.50–1.37; P=0.47), but letaxaban dose-dependently
increased the rate of combined TIMI major and minor
bleeding compared with placebo (2.1% versus 0.9%; 95% CI,
1.53–2.86, P=0.025).
Direct Oral Thrombin (FIIa) Inhibition
Direct oral thrombin (FIIa) inhibitors are a class of anticoag-
ulants that act by directly inhibiting thrombin to delay clotting.
The efﬁcacy and safety of the direct thrombin inhibitor
dabigatran was evaluated in RE-DEEM (Randomized Dabiga-
tran Etexilate Dose Finding Study in Patients With Acute
Coronary Syndromes Post Index Event With Additional Risk
Factors for Cardiovascular Complications Also Receiving
Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo
Controlled, Cohort Dose Escalation Study).31 This phase II,
randomized, double-blind, placebo-controlled trial of 1861
patients with recent ACS assessed the addition of different
doses of dabigatran (50, 75, 110, and 150 mg BID) to DAPT
that included clopidogrel.
Dabigatran dose-dependently increased major bleeding
compared with placebo (P<0.001) but did not reduce the
composite end point of cardiovascular death, nonfatal MI and
nonhemorrhagic stroke compared with placebo (4% versus
3.8%; P value not signiﬁcant). Dabigatran thus has no role in
ACS and currently is not indicated for patients on DAPT
because of a doubling of major bleeding risk noted in the ESC
and ACC/AHA guidelines.10,11,20,26
Non–Vitamin K Oral Anticoagulant Meta-Analysis
A meta-analysis of 7 randomized, placebo-controlled, phase II
and III studies of different non–vitamin K oral anticoagulants
(FXa inhibitors apixaban, darexaban, rivaroxaban, and FIIa
inhibitors dabigatran and ximelagatran) in ACS showed that
addition of a non–vitamin K oral anticoagulant to DAPT for
6 months prevented 5 major adverse cardiovascular events
and caused 42 additional clinically signiﬁcant bleeding events
per 1000 patients treated.32 The authors followed the princi-
ples of DerSimonian and Laird, using a random effect model,
and reported pooled hazard ratios of the studies. However,
there was no access to patient-level data, and results should be
interpreted with caution, given the limitations of a meta-
analysis mixing phase II and III studies of drugs at different
doses and with differing pharmacodynamics.
Discussion
TT combinations comprising the addition of an oral anticoag-
ulant—in particular, low-dose rivaroxaban or PAR-1 antago-
nist to DAPT, predominantly aspirin and clopidogrel—
generally increase bleeding with, at best, a modest effect
reducing ischemic end points in ACS patients (Figure 2).
However, there was a lack of uniformity in the deﬁnition of
bleeding among the reported trials, making indirect compar-
isons of relative bleeding with different agents challenging.
The deﬁnition of bleeding events has variably included
laboratory parameters, such as decrease in hemoglobin, and
clinical events, including the need for transfusion, surgery,
cardiac tamponade, and hematoma. Standardization of
bleeding reports using the BARC (Bleeding Academic
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Research Consortium) system would have been highly desir-
able but was not available at the time of some of these
studies.33 Although it remains clear, regardless of the
deﬁnitions used, that TT signiﬁcantly increases the risk of
bleeding compared with DAPT, the lack of uniformity in
bleeding deﬁnition coupled with the lack of direct head-to-
head comparisons of TT combinations makes it impossible to
compare bleeding risk with different strategies.
There has also been heterogeneity in the deﬁnition of
primary efﬁcacy outcomes. Although some studies included
only “hard” clinical end points of major adverse cardiovascular
events, others included more “soft” end points such as
revascularization or hospitalization. Some included ischemic
strokes only, and others included all strokes.
Overall, the risk–beneﬁt ratio suggests that it may be
reasonable to justify the use of rivaroxaban in TT combination
for high-risk ACS patients who are at low bleeding risk, and
vorapaxar could be considered for patients with prior MI but
not in the acute or subacute phase of ACS, with some
restrictions.20 Rivaroxaban and vorapaxar should not be
considered as add-on therapy in combination with P2Y12
inhibitors other than clopidogrel because data are lacking and
bleeding would be expected to increase disproportionately.
However, adding warfarin to DAPT appears not to be justiﬁed,
as the WOEST study not only demonstrated a higher risk of
bleeding with TT but also ischemic end points occurred less
frequently with oral anticoagulation combined with a single
antiplatelet agent.14
Identifying the Right Patient
The trials assessing TT studied patients with recent ACS and ≥1
additional risk factor. Although several risk stratiﬁcation scores
are available to assess the risk of recurrent ischemic events in
ACSpatients, suchasGRACE (Global Registry ofAcuteCoronary
Events), PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable
Angina:ReceptorSuppressionUsing Integrilin Therapy) andTIMI
scores, none of these were used to identify and target those
patients with ACS who were truly at high risk. Platelet function
tests canalso identify patientsonclopidogrel at increased riskof
MI, stent thrombosis, and cardiovascular death.34,35 However,
altering pharmacotherapy based on the results of platelet-
function testing failed to reduce recurrent ischemic events in
patients undergoing PCI, including for ACS,36,37 and current
guidelines do not support platelet-function testing.15,38 Finally,
patientsundergoingcomplexPCI (deﬁnedas thecomposite of at
least 3 stents implanted, at least 3 lesions treated, bifurcation
with 2 stents implanted, total stent length>60 mm, and chronic
totalocclusionastarget lesion)38,39orpriorstent thrombosisare
clearly at increased risk of thrombosis,38 and although consid-
eration may be given to longer total duration of DAPT treatment
in these patients, the option of TT has not been speciﬁcally
evaluated. The increased risk of bleeding is a signiﬁcant concern
withmoreeffectiveantithromboticagentcombinations.Someof
this excess bleeding could perhaps potentially be mitigated, at
least in part, by careful bleeding risk assessment and use of
gastric protection. Because the predominant source of bleeding
isgastrointestinal,mandating theuseofgastricprotectionwitha
proton pump inhibitor would seem pragmatic22 but was not
routinely done in any study. The new 2017 ESC guidelines now
clearly recommend the routineuseof aprotonpump inhibitor for
patients taking DAPT, as level of evidence class I, level B,38
whereas the ACC/AHA 2016 guidelines recommend that “in
patients with increased risk of gastrointestinal bleeding, includ-
ing those with advanced age and those with concomitant use of
warfarin, steroids, or nonsteroidal anti-inﬂammatory drugs, use
of PPIs [proton pump inhibitors] is reasonable (Class IIa)”.15
In addition, avoiding more potent antiplatelet therapies in
patients with prior gastrointestinal bleed or intracranial
hemorrhage also seems prudent, and such patients were
excluded from most recent trials. Risk scores are available
and may be considered to identify patients at high bleeding
risk.38 The PRECISE-DAPT (Predicting Bleeding Complications
in Patients Undergoing Stent Implantation and Subsequent
Dual Antiplatelet Therapy)40 or PARIS (Patterns of Nonadher-
ence to Antiplatelet Regimen in Stented Patients)41 scores in
patients receiving coronary stents and treated with DAPT have
been shown to be predictive of bleeding, but prospective
validation in randomized controlled trials is lacking.38 Other
risk scores for bleeding can be helpful, including HASBLED
(Hypertension, Abnormal liver/renal function, Stroke history,
Bleeding predisposition, Labile international normalized ratio,
Elderly, Drug/alcohol usage),42 validated predominantly in
patients with atrial ﬁbrillation taking warfarin, or CRUSADE
(Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the
ACC/AHA Guidelines) and ACUITY (Acute Catheterization and
Urgent Intervention Triage Strategy) scores in ACS patients
undergoing coronary angiography.43,44 There is clearly a need
to identify circulating biomarkers that reﬂect platelet, inﬂam-
matory, coagulation, and endothelial function that identify
patients at risk of bleeding and thrombosis and to incorporate
those markers into trials for prospective validation.
Identifying the Right Drug Combination
The control arms in the reported trials, against which TT was
compared, have mostly included patients receiving a combi-
nation of aspirin and clopidogrel,21–23,28–31,45 but current
guidelines recommend ticagrelor or prasugrel over clopidogrel
in ACS.15,20,26,38 Consequently, any new combination regimen
should be compared with “current best.” The combination of a
non–vitamin K oral anticoagulant with DAPT that includes
these more effective P2Y12 inhibitors may increase bleeding
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compared with clopidogrel, but this has never been tested.
Furthermore, the efﬁcacy and safety proﬁle of DAPT including
ticagrelor or prasugrel versus TT remains unknown.
Studies to date have shown modest absolute reduction in
ischemic end points when DAPT was combined with oral
anticoagulants, offset by increased bleeding. In the current
era of combined antithrombotic and antiplatelet therapy, it
remains unclear whether there is still a need for conventional
treatment with aspirin and whether this can be replaced by
more advanced combination therapy.46 Two recent trials
aiming to show the superiority of ticagrelor compared with
aspirin or clopidogrel as single antiplatelet therapy in the
setting of recent stroke (6.7% versus 7.5%; 95% CI, 0.78–1.01;
P=0.07)47 and peripheral arterial disease (10.8% versus
10.6%; 95% CI, 0.92–1.13; P=0.65),48 respectively, did not
show a statistical difference. Despite the clear superiority of
ticagrelor over clopidogrel exhibited in PLATO (Platelet
Inhibition and Patient Outcomes),49 in the acute setting,
results from the recent CHANGE DAPT (Change of Dual
Antiplatelet Therapy in Patients With Acute Coronary Syn-
drome) trial have reinitiated the argument about the preferred
antiplatelet therapy in the era of the new drug-eluting stents
with thinner struts, mitigating against stent thrombosis.50
The duration of the preferred antithrombotic regimen is
another important aspect of choosing the right regimen for the
right patient, for whom prolonged treatment with DAPT reduces
ischemic end points at the cost of increased bleeding, as
exhibited in thePEGASUSTIMI-54 (PreventionofCardiovascular
Events in Patients with Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin–Thrombolysis
in Myocardial Infarction 54)51 study. The 2017 ESC guideline
states that prolonged duration of DAPT may be considered for
patients at high thrombotic risk, such as those undergoing
complex PCI or those implanted with a bioresorbable vascular
scaffold,38 and particularly for those who have tolerated DAPT
without a bleeding complication.38
The ongoing open-label trial GLOBAL LEADERS (Compar-
ative Effectiveness of 1 Month of Ticagrelor Plus Aspirin
Followed by Ticagrelor Monotherapy Versus a Current-Day
Intensive Dual Antiplatelet Therapy in All-Comers Patients
Undergoing Percutaneous Coronary Intervention With Bivalir-
udin and BioMatrix Family Drug-Eluting Stent Use) aims to
assess the role of ticagrelor as a single antiplatelet agent for
2 years after a 1-month course of DAPT (comprising ticagrelor
and aspirin) for the long-term prevention of cardiac adverse
events. The study (n>16 000) recruited all-comers undergoing
PCI, both for elective and ACS indications, who all received
bivalirudin and a biomatrix stent.52
Patients were then randomized to ticagrelor 90 mg BID for
24 months plus aspirin for 1 month versus DAPT with either
ticagrelor or clopidogrel for 12 months plus aspirin for
24 months. The primary outcome is a composite of all-cause
mortality or nonfatal MI, and the safety end point is major
bleeding.
Finally, edoxaban, another FXa inhibitor, is being evaluated
in a phase II trial, together with aspirin and clopidogrel, in
ACS.53
Conclusions and Future Directions
In patients with recent ACS for which DAPT is the current
standard of care, the use instead of TT—with the addition of an
oral anticoagulant, PAR-1 antagonist, or cilostazol—has been
investigated with the aim of reducing future ischemic events.
Except for cilostazol, which gave neutral results in terms of
safety and efﬁcacy, TT leads to a signiﬁcant increase in
bleeding, and this is unacceptably high with vorapaxar and with
warfarin. Rivaroxaban 2.5 mg twice daily can be considered in
combination with aspirin and clopidogrel for ACS patients who
have high ischemic and low bleeding risk. There is a clear signal
that TT can reduce ischemic events, but the excessive bleeding
seems to offset the potential beneﬁt.
There is an absolute necessity for improved, more accurate
risk stratiﬁcation of patients, for both future ischemic events
and bleeding, to allow targeted individualized treatment.
Future trials should focus even more stringently on
identifying patients at high ischemic and low bleeding risk
who may gain the most from newer antithrombotic agent
combinations. In addition to risk scores in ACS such as
GRACE and TIMI, angiographic features associated with
recurrent thrombosis, such as diameter and length of stented
segment, stent underexpansion, and completeness of revas-
cularization, as well as circulating (bio)markers could be
incorporated into risk assessment to identify patients who
would gain most.
Because clinically meaningful bleeding remains a concern
with more effective antithrombotic agent combinations,
accurate bleeding risk stratiﬁcation and perhaps mandated
prophylactic use of proton pump inhibitors should be applied
universally. Unfortunately, most clinical risk factors included
in several bleeding scores are also risk factors for thrombosis
(eg, age, hypertension, prior thromboembolism). Further
validation of circulating biomarkers would be relevant to
better risk stratify patients and separate bleeding and
thrombosis risk. Moving away from TT, we await the results
of novel combination therapies involving direct oral FXa or FIIa
inhibitors and a P2Y12 inhibitor, not only in the setting of atrial
ﬁbrillation but also in patients with ACS at high ischemic and
low bleeding risk.
Disclosures
None.
DOI: 10.1161/JAHA.117.007754 Journal of the American Heart Association 8
Dual vs Triple Therapy in ACS Spinthakis et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
D
ow
nloaded from
 http://ahajournals.org by on April 18, 2019
References
1. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management,
part I. Mayo Clin Proc. 2009;84:917–938.
2. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D,
Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane
AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during
primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–
2230.
3. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects
accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6:3–11.
4. Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R. Cilostazol added to
aspirin and clopidogrel reduces revascularization without increases in major
adverse events in patients with drug-eluting stents: a meta-analysis of
randomized controlled trials. Int J Cardiol. 2013;167:2250–2258.
5. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH,
Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS. Multicenter
randomized trial evaluating the efﬁcacy of cilostazol on ischemic vascular
complications after drug-eluting stent implantation for coronary heart disease:
results of the CILON-T (inﬂuence of CILostazol-based triple antiplatelet therapy
ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll
Cardiol. 2011;57:280–289.
6. Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew
JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY,
Park TH, Moon KW, Kwon HM, Chae IH, Kim HS. Adjunctive cilostazol versus
double-dose clopidogrel after drug-eluting stent implantation: the HOST-
ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of
Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-
platelet Regimen). JACC Cardiovasc Interv. 2013;6:932–942.
7. Fan ZG, Ding GB, Li XB, Gao XF, Gao YL, Tian NL. The clinical outcomes of
triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients
after coronary stent implantation: a meta-analysis of 11 clinical trials and
9,553 patients. Drug Des Devel Ther. 2016;10:3435–3448.
8. Chen J, Meng H, Xu L, Liu J, Kong D, Chen P, Gong X, Bai J, Zou F, Yang Z, Li C,
Eikelboom JW. Efﬁcacy and safety of cilostazol based triple antiplatelet
treatment versus dual antiplatelet treatment in patients undergoing coronary
stent implantation: an updated meta-analysis of the randomized controlled
trials. J Thromb Thrombolysis. 2015;39:23–34.
9. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm
C, Head SJ, J€uni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G,
Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP,
Torracca L, Valgimigli M, Wijns W, Witkowski A; Authors/Task Force Members.
2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force
on Myocardial Revascularization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery (EACTS). Developed
with the special contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
10. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR,
Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D,
Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force
Members. 2014 AHA/ACC guideline for the management of patients with non-
ST-elevation acute coronary syndromes: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines.
Circulation. 2014;130:e344–e426.
11. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA,
Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM,
Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-
Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK,
Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA,
Hochman JS, Kovacs RJ, Ohman EM, Stevenson WG, Yancy CW; American
College of Emergency Physicians; Society for Cardiovascular Angiography and
Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation
myocardial infarction: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2013;61:e78–e140.
12. Hirsh J,Dalen JE,DeykinD,PollerL.Oralanticoagulants.Mechanismofaction,clinical
effectiveness, and optimal therapeutic range. Chest. 1992;102:312S–326S.
13. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen
C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C, Gislason GH. Risk of
bleeding in patients with acute myocardial infarction treated with different
combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a
retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–
1974.
14. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP,
Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van ‘t Hof AW,
ten Berg JM; WOEST study investigators. Use of clopidogrel with or without
aspirin in patients taking oral anticoagulant therapy and undergoing
percutaneous coronary intervention: an open-label, randomised, controlled
trial. Lancet. 2013;381:1107–1115.
15. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB,
Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT,
Sabatine MS, Smith PK, Smith SC. 2016 ACC/AHA guideline focused update
on duration of dual antiplatelet therapy in patients with coronary artery
disease: a report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines: an update of the 2011
ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011
ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/
AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and manage-
ment of patients with stable ischemic heart disease, 2013 ACCF/AHA
guideline for the management of ST-elevation myocardial infarction, 2014
AHA/ACC guideline for the management of patients with non-ST-elevation
acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative
cardiovascular evaluation and management of patients undergoing noncardiac
surgery. Circulation. 2016;134:e123–e155.
16. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA,
Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux
P, Wiviott SD, Strony J, Murphy SA; Investigators TPTSCa. Vorapaxar in the
secondary prevention of atherothrombotic events. N Engl J Med.
2012;366:1404–1413.
17. Farag M, Patel H, Gorog DA. Adjunctive therapies to reduce thrombotic events
in patients with a history of myocardial infarction: role of vorapaxar. Drug Des
Devel Ther. 2015;9:3801–3809.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin
Trials. 2015;45:139–145.
19. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White
HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick
TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R,
Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM,
Montalescot G, Nicolau JC, Ogawa H, Pﬁsterer M, Prieto JC, Ruzyllo W,
Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J,
Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor
antagonist vorapaxar in acute coronary syndromes. N Engl J Med.
2012;366:20–33.
20. Rofﬁ M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ,
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K,
Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S,
Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C,
Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol C, Fitzsimons D,
Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS,
Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis
Zamorano J; Management of Acute Coronary Syndromes in Patients
Presenting without Persistent ST-Segment Elevation of the European Society
of Cardiology. 2015 ESC guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment elevation:
Task Force for the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J. 2016;37:267–315.
21. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P,
Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN,
Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51
Investigators. Rivaroxaban in patients with a recent acute coronary
syndrome. N Engl J Med. 2012;366:9–19.
22. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman
S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De
Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-
Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White
H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2
Investigators. Apixaban with antiplatelet therapy after acute coronary
syndrome. N Engl J Med. 2011;365:699–708.
23. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak
V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson
CM; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients
with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-
blind, phase II trial. Lancet. 2009;374:29–38.
24. Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG,
Parkhomenko A, Tendera M, Widimsky P, Gibson CM. Rivaroxaban in patients
stabilized after a ST-segment elevation myocardial infarction: results from the
ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in
Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-
Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol. 2013;61:1853–
1859.
25. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt
DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E;
Investigators A-AT. Reduction of stent thrombosis in patients with acute
coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am
Coll Cardiol. 2013;62:286–290.
DOI: 10.1161/JAHA.117.007754 Journal of the American Heart Association 9
Dual vs Triple Therapy in ACS Spinthakis et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
D
ow
nloaded from
 http://ahajournals.org by on April 18, 2019
26. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H,
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A,
Lenzen MJ, Prescott E, Rofﬁ M, Valgimigli M, Varenhorst C, Vranckx P,
Widimsky P; Group ESD. 2017 ESC guidelines for the management of acute
myocardial infarction in patients presenting with ST-segment elevation: the
Task Force for the management of acute myocardial infarction in patients
presenting with ST-segment elevation of the European Society of Cardiology
(ESC). Eur Heart J. 2017. Available at: https://academic.oup.com/eurheartj/
article/39/2/119/4095042. Accessed January 19, 2018.
27. Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F,
Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G,
Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss
RG, G€uray €U, Park DW, Bode C, Welsh RC, Gibson CM. Clinically signiﬁcant
bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12
inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind,
multicentre, randomised trial. Lancet. 2017;389:1799–1808.
28. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA,
Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J,
Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L; APPRAISE
Steering Committee and Investigators. Apixaban, an oral, direct, selective
factor Xa inhibitor, in combination with antiplatelet therapy after acute
coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic
and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–2885.
29. Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-
Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. RUBY-1: a
randomized, double-blind, placebo-controlled trial of the safety and tolerability
of the novel oral factor Xa inhibitor darexaban (YM150) following acute
coronary syndrome. Eur Heart J. 2011;32:2541–2554.
30. Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, Martinez F,
Spaeder J, Weitz JI, Ye Z, Zannad F; AXIOM investigators. Phase 2 study of TAK-
442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
Thromb Haemost. 2014;111:1141–1152.
31. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van
de Werf F, Wallentin L; RE-DEEM Investigators. Dabigatran vs. placebo in
patients with acute coronary syndromes on dual antiplatelet therapy: a
randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781–2789.
32. Oldgren J, Wallentin L, Alexander JH, James S, J€onelid B, Steg G, Sundstr€om J.
New oral anticoagulants in addition to single or dual antiplatelet therapy after
an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart
J. 2013;34:1670–1680.
33. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S,
Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P,
Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H.
Standardized bleeding deﬁnitions for cardiovascular clinical trials: a consensus
report from the Bleeding Academic Research Consortium. Circulation.
2011;123:2736–2747.
34. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function
monitoring in patients with coronary artery disease. J Am Coll Cardiol.
2007;50:1822–1834.
35. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL,
Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK,
Kereiakes D, Sibbing D, TrenkD, VanWerkum JW, Paganelli F, PriceMJ,Waksman
R, Gurbel PA; Working Group on High On-Treatment Platelet Reactivity.
Consensus and future directions on the deﬁnition of high on-treatment platelet
reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–933.
36. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P,
CarrieD,Boueri Z,Belle L,VanBelle E,RousseauH,AubryP,Monsegu J, SabouretP,
O’ConnorSA, Abtan J, KerneisM,Saint-EtienneC, BarthelemyO, Beygui F, Silvain J,
Vicaut E, Montalescot G; ARCTIC Investigators. Bedside monitoring to adjust
antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–2109.
37. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C,
Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrie D, Belle L,
Souteyrand G, Aubry P, Sabouret P, du Fretay XH, Beygui F, Bonnet JL, Lattuca
B, Pouillot C, Varenne O, Boueri Z, Van Belle E, Henry P, Motreff P, Elhadad S,
Salem JE, Abtan J, Rousseau H, Collet JP, Vicaut E, Montalescot G; ANTARCTIC
investigators. Platelet function monitoring to adjust antiplatelet therapy in
elderly patients stented for an acute coronary syndrome (ANTARCTIC): an
open-label, blinded-endpoint, randomised controlled superiority trial. Lancet.
2016;388:2015–2022.
38. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, J€uni P, Kastrati
A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Rofﬁ M, Steg PG,
Windecker S, Zamorano JL, Levine GN; Group ESD, (CPG) ECfPG, Societies
ENC. 2017 ESC focused update on dual antiplatelet therapy in coronary artery
disease developed in collaboration with EACTS: the Task Force for dual
antiplatelet therapy in coronary artery disease of the European Society of
Cardiology (ESC) and of the European Association for Cardio-Thoracic
Surgery (EACTS). Eur Heart J. 2017. Available at: https://academic.oup.
com/eurheartj/article/39/3/213/4095043. Accessed January 19, 2018.
39. Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, Costa RA,
Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Gilard M, Morice MC, Sawaya F,
Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, Stone GW, Colombo A.
Efﬁcacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll
Cardiol. 2016;68:1851–1864.
40. Costa F, van Klaveren D, James S, Heg D, R€aber L, Feres F, Pilgrim T, Hong MK,
Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL,
Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study
Investigators. Derivation and validation of the predicting bleeding complica-
tions in patients undergoing stent implantation and subsequent dual
antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-
patient datasets from clinical trials. Lancet. 2017;389:1025–1034.
41. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C,
Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ,
Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG,
Pocock S. Coronary thrombosis and major bleeding after PCI with drug-
eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224–
2234.
42. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-
friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients
with atrial ﬁbrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100.
43. Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E, Guastaroba P, De Palma R,
Ando G, Oreto G, Zijlstra F, Valgimigli M. Incremental value of the CRUSADE,
ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic
events after coronary stent implantation in patients undergoing long or
short duration of dual antiplatelet therapy. J Am Heart Assoc. 2015;4:
e002524. DOI: 10.1161/JAHA.115.002524.
44. Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores.
Lancet. 2017;389:987–989.
45. Ogawa H, Goto S, Matsuzaki M, Hiro S, Shima D; APPRAISE-J Investigators.
Randomized, double-blind trial to evaluate the safety of apixaban with
antiplatelet therapy after acute coronary syndrome in Japanese patients
(APPRAISE-J). Circ J. 2013;77:2341–2348.
46. Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman
EM. A critical reappraisal of aspirin for secondary prevention in patients with
ischemic heart disease. Am Heart J. 2016;181:92–100.
47. Culic V. Ticagrelor versus aspirin in acute stroke or transient ischemic attack.
N Engl J Med. 2016;375:1394–1395.
48. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG,
Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegard M, Reist C, Patel MR;
EUCLID Trial Steering Committee and Investigators. Ticagrelor versus
clopidogrel in symptomatic peripheral artery disease. N Engl J Med.
2017;376:32–40.
49. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J,
Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
Storey RF, Harrington RA, Freij A, Thorsen M; PLATO Investigators. Ticagrelor
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med.
2009;361:1045–1057.
50. Zocca P, van der Heijden LC, Kok M, Lowik M, Hartmann M, Stoel M,
Louwerenburg H, de Man F, Linssen G, Knottnerus I, Doggen C, Van
Houwelingen G, Von Birgelen C. Clopidogrel or ticagrelor in acute coronary
syndrome patients treated with newer-generation drug-eluting stents:
CHANGE DAPT. EuroIntervention. 2017;13:1168–1176.
51. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G,
Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P,
Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott
SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee
and Investigators. Long-term use of ticagrelor in patients with prior myocardial
infarction. N Engl J Med. 2015;372:1791–1800.
52. ECRI. Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin
Followed by Ticagrelor Monotherapy Versus a Current-Day Intensive Dual
Antiplatelet Thepary in All-Comers Patients Undergoing Percutaneous
Coronary Intervention With Bivalirudin and Biomatrix Family Drug-Eluting
Stent Use (Global Leaders: A Clinical Study Comparing Two Forms of Anti-
platelet Therapy After Stent Implantation). Cited [March 19, 2013]. Available
at: https://clinicaltrials.gov/ct2/show/NCT01813435. NLM identiﬁer:
NCT01813435. Accessed January 19, 2018.
53. Florida Uo. Edoxaban in Patients With Coronary Artery Disease on Dual
Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT). Cited [October
1, 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT02567461
NLM identiﬁer: NCT02567461. Accessed January 19, 2018.
Key Words: acute coronary syndrome • anticoagulation •
dual antiplatelet therapy • thrombosis
DOI: 10.1161/JAHA.117.007754 Journal of the American Heart Association 10
Dual vs Triple Therapy in ACS Spinthakis et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
D
ow
nloaded from
 http://ahajournals.org by on April 18, 2019
